Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Commentary on the River Stent Trial: Venous Sinus Stenting is Safe and Effective and can be Fully Evaluated Using Noninvasive Methods
Amans, Matthew R. , Levitt, Michael R. , Hirsch, Joshua A , Mocco, J , Fiorella, David , Altschul, David , Altschul, Dorothea , Chen, Michael , Leacy, Reade De , Narsinh, Kazim , Brinjikji, Waleed , Telischak, N , Amans, Matthew , Levitt, Michael R , Mocco, J , De Leacy, Reade , Arthur, Adam Stephen , Narsinh, Kazim H , Brinjikji, Waleed , Milburn, James M , Hui, Ferdinand , Fiorella, David , Altschul, David J , Abraham, Michael G. , Hui, Ferdinand

Journal of NeuroInterventional Surgery | April 30, 2025 | Volume: 17 | Issue: 8 | Pages: 790-791

10.1136/jnis-2025-023433 | PMID 40306927 Get It

Higher risk of recurrence in partially thrombosed cerebral aneurysms post-WEB (Woven EndoBridge) device treatment: insights from the WorldWideWEB Consortium registry
Saliou, Guillaume , Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Aslan, Assala , Swaid, Christian, Cuellar, Miguel, Dibas, Mahmoud , Cancelliere, Nicole M , Diestro, Jose Danilo Bengzon , Lay, Sovann V. , Guenego, Adrien , Möhlenbruch, Markus , Kral, Michael , Salem, Mohamed M , Foreman, Paul M. , Shaikh, Hamza , Župančić, Vedran , Rabinov, James D. , Ren, Yifan , Michelozzi, Caterina , Starke, Robert M. , Ogilvie, Mark , Nguyên, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Psychogios, Marios‐Nikos , Ulfert, Christian , Pukenas, Bryan , Burkhardt, Jan Karl, Slawski, Diana , Pulli, Benjamin , Lubicz, Boris , Puri, Ajit S , Pero, Guglielmo , Raz, Eytan , Asadi, Hamed , Siddiqui, Adnan H. , Haranhalli, Neil , Altschul, David , Ducruet, Andrew F. , Albuquerque, Felipe C , Regenhardt, Robert W. , Stapleton, Christopher J. , Kan, Peter , Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Knopman, Jared , Tjoumakaris, Stavropoula , Jabbour, Pascal , Clarençon, Frédéric , Patel, Aman B. , Salim, Hamza , Ghozy, Sherief , Lay, Sovann V , Guenego, Adrien , Carnevale, Joseph Anthony , ElNaamani, Kareem , Shotar, Eimad , Chung, Charlotte , Salem, Mohamed M , Lylyk, Ivan , Shaikh, Hamza A , Hafeez, Muhammad U , Catapano, Joshua S , Ren, Yifan , Schirmer, Clemens M , Michelozzi, Caterina , Hassan, Ameer E , Ogilvie, Mark , Nguyen, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Huynh, Thien J, Martinez-Gutierrez, Juan Carlos , Essibayi, Muhammed Amir , Sheth, Sunil A , Tawk, Rabih G , Pulli, Benjamin , Pero, Guglielmo , Raz, Eytan , Griessenauer, Christoph J , Siddiqui, Adnan H , Levy, Elad I , Albuquerque, Felipe C , Stapleton, Christopher , Kan, Peter , Kalousek, Vladimir , Tjoumakaris, Stavropoula , Cuellar-Saenz, Hugo H , Jabbour, Pascal , Dmytriw, Adam A , Hajdu, Steven D , Dibas, Mahmoud , Diestro, Jose Danilo B , Saliou, Guillaume , Altschul, David J , Musmar, Basel , Regenhardt, Robert W , Cancelliere, Nicole M , Ulfert, Christian , Burkhardt, Jan‐Karl , Cuellar, Miguel, Algin, Oktay , Ghozy, Sherief , Renieri, Leonardo , Mastorakos, Panagiotis , Naamani, Kareem El , Shotar, Eimad , Lylyk, Iván , Hafeez, Muhammad Ubaid , Waqas, Muhammad , Arslan, Muhammet , Ergün, Onur , Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna Luisa , Hassan, Ameer E , Huynh, Thien , Essibayi, Muhammed Amir , Tawk, Rabih G. , Panni, Pietro , Griessenauer, Christoph J. , Levy, Elad I. , Cuellar, Hugo , Limbucci, Nicola , Mendes Pereira, Vitor , Dmytriw, Adam A.

Journal of NeuroInterventional Surgery | April 30, 2025 | Volume: 18 | Issue: 3 | Pages: 782-789

10.1136/jnis-2024-022628 | PMID 40306928 Get It

Background The Woven EndoBridge (WEB) device is a prevalent treatment for intracranial aneurysms. While many studies have assessed the obliteration rate post-WEB embolization, few have focused on long-term outcomes in partially thrombosed aneurysms. Objective To assess whether partially thrombosed aneurysms are at higher risk of recurrence or retreatment following WEB embolization compared with non-thrombosed aneurysms. Methods We evaluated data from 22 academic institutions, focusing on previously untreated cerebral aneurysms treated with the WEB device. Logistic regression was utilized to analyze factors predicting long-term aneurysm obliteration and retreatment necessity. Results Among 1303 patients, 26 presented with a partially thrombosed aneurysm. In the partially thrombosed group, the mean aneurysm maximal diameter was 10.7±4 mm with a neck ratio of 1.99±1.19 mm, larger than in the control group where the mean aneurysm maximal diameter was 6.81±2.37 mm with a neck ratio of 1.64±0.51 mm (P<0.001 for both maximal diameter and neck ratio). At the final follow-up, partially thrombosed aneurysms treated by the WEB device had a 38.5% retreatment rate, compared with 7.0% for non-thrombosed aneurysms (P<0.001). Among partially thrombosed aneurysms, the Raymond-Roy type IIIa/b occlusion rate was higher (38.5% vs 9.9%, P<0.001). On multivariate analysis, partially thrombosed aneurysms compared with non-thrombosed aneurysms had an increased rate of retreatment (OR 3.64, 95% CI 1.28 to 10.1). Conclusion Partially thrombosed aneurysms are associated with a poorer occlusion rate and a higher rate of retreatment following WEB embolization. For partially thrombosed aneurysms, the WEB device appears suboptimal as a first-line treatment, and therefore alternative techniques should be prioritized.
Impact of Long‐Term Use of Anticoagulants Among Elderly Patients Undergoing Left Atrial Appendage Occlusion Procedures in the United States: A Retrospective Cohort Study
Mehta, Samay , Sekhon, Manraj, Rajotia, Arush , Gandhi, Haresh , Raj, Kavin , Singh, Jarmanjeet , Verma, Renuka, Sakthivel, Hemamalini, Ramphul, Kamleshun, Singh, Swaiman, Mehta, Samay , Dhaliwal, Jasninder Singh , Sekhon, Manraj, Ahmed, Mushood , Ahmed, Raheel

Health Science Reports | April 30, 2025 | Volume: 8 | Issue: 5 | Pages: No page available

10.1002/hsr2.70812 | PMID 40309619 Get It

Unsupervised Generative Approach for Anomaly Detection to Enhance the Quality of Unseen Medical Datasets
Zhang, Zhemin , Patel, Bhavik N. , Patel, Bhavika , Banerjee, Imon

2025 IEEE/CVF Winter Conference on Applications of Computer Vision Workshops (WACVW) | April 29, 2025 | Volume: No volume available | Issue: No issue available | Pages: 250-259

10.1109/wacvw65960.2025.00035 Get It

UNISOM: Unified Somatic Calling and Machine Learning-based Classification Enhance the Discovery of CHIP
Tian, Shulan , Jenkinson, Garrett , Ferrer, Alejandro Tiana, Yan, Huihuang , Morales‐Rosado, Joel A. , Wang, Kevin L. , Lasho, Terra L. , Yan, Benjamin B. , Baheti, Saurabh , Olson, Janet E. , Patnaik, Mrinal M. , Klee, Eric W. , Ferrer, Alejandro , Ferrer, Alejandro , Baughn, Linda B , Ding, Wei , Slager, Susan L , Patnaik, Mrinal , Lazaridis, Konstantinos N , Klee, Eric W , Olson, Janet E , Lasho, Terra L , Tian, Shulan , Morales-Rosado, Joel A , Baughn, Linda B. , Slager, Susan L. , Lazaridis, Konstantinos N.

Genomics, Proteomics & Bioinformatics | April 29, 2025 | Volume: 23 | Issue: 2 | Pages: No page available

10.1093/gpbjnl/qzaf040 | PMID 40300108 Get It

Abstract Clonal hematopoiesis (CH) of indeterminate potential (CHIP), driven by somatic mutations in leukemia-associated genes, confers increased risk of hematologic malignancies, cardiovascular disease, and all-cause mortality. In blood of healthy individuals, small CH clones can expand over time to reach 2% variant allele frequency (VAF), the current threshold for CHIP. Nevertheless, reliable detection of low-VAF CHIP mutations is challenging, often relying on deep targeted sequencing. Here, we present UNISOM, a streamlined workflow for enhancing CHIP detection from whole-genome and whole-exome sequencing data that are underpowered, especially for low VAFs. UNISOM utilizes a meta-caller for variant detection, in couple with machine learning models which classify variants into CHIP, germline, and artifact. In whole-exome sequencing data, UNISOM recovered nearly 80% of the CHIP mutations identified via deep targeted sequencing in the same cohort. Applied to whole-genome sequencing data from Mayo Clinic Biobank, it recapitulated the patterns previously established in much larger cohorts, including the most frequently mutated CHIP genes and predominant mutation types and signatures, as well as strong associations of CHIP with age and smoking status. Notably, 30% of the identified CHIP mutations had &lt; 5% VAFs, demonstrating its high sensitivity toward small mutant clones. This workflow is applicable to CHIP screening in population genomic studies. The UNISOM pipeline is freely available at https://github.com/shulanmayo/UNISOM and https://ngdc.cncb.ac.cn/biocode/tool/7816.
AASLD Practice Statement on the evaluation and management of metabolic dysfunction–associated steatotic liver disease in children
Xanthakos, Stavra A. , Ibrahim, Samar H. , Kohli, Rohit, Sathya, Pushpa , Sundaram, Shikha S. , Vos, Miriam B. , Dhawan, Ashish, Caprio, Sonia , Behling, Cynthia , Kohli, Rohit , Kohli, Rohit , Sundaram, Shikha , Vos, Miriam B , Dhawan, Ashish , Behling, Cynthia A , Schwimmer, Jeffrey B , Ibrahim, Samar H , Adams, Kathryn, Schwimmer, Jeffrey B.

Hepatology | April 29, 2025 | Volume: 82 | Issue: 5 | Pages: 1352-1394

10.1097/hep.0000000000001368 | PMID 40300071 Get It

Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer
Moding, Everett J. , Esfahani, Mohammad Shahrokh , Jin, Cheng , Hui, Angela B. , Nabet, Barzin Y. , Liu, Yufei , Chabon, Jacob J. , Binkley, Michael S. , Kurtz, David M. , Hamilton, Emily G. , Chaudhuri, Aadel A. , Liu, Chih Long , Bonilla, Rene F., Jiang, Alice L. , Lau, Brianna , Lopez, Pablo , He, Jianzhong, Qiao, Yawei, Yao, Luyang , Gandhi, Saumil , Das, Millie , Ramchandran, Kavitha , Padda, Sukhmani K. , Neal, Joel W. , Wakelee, Heather A. , Li, Ruijiang , Alizadeh, Ash A. , Shahrokh Esfahani, Mohammad , Li, Zhe , Bonilla, Rene F , Jiang, Alice L , Lau, Brianna C , Lopez, Pablo , He, Jianzhong , Qiao, Yawei , Xu, Ting , Yao, Luyang , Gandhi, Saumil , Liao, Zhongxing , Das, Millie , Ramchandran, Kavitha J , Padda, Sukhmani K , Neal, Joel W , Wakelee, Heather A , Gensheimer, Michael F , Loo, Billy W , Li, Ruijiang , Lin, Steven H , Alizadeh, Ash A , Diehn, Maximillian , Binkley, Michael Sargent , Kurtz, David M , Loo, Billy W. , Lin, Steven H. , Diehn, Maximilian

Cancer Discovery | April 29, 2025 | Volume: 15 | Issue: 8 | Pages: 1609-1629

10.1158/2159-8290.cd-24-1704 | PMID 40299851 Get It

Abstract The complementarity and clinical utility of combining liquid biopsies and radiomic image analysis has not been demonstrated. ctDNA minimal residual disease after chemoradiotherapy (CRT) for non–small cell lung cancer (NSCLC) is highly prognostic, but on-treatment biomarkers are needed to enable response-adapted therapies. In this study, we analyzed 418 patients with NSCLC undergoing CRT to develop and validate a novel dynamic risk model that accurately predicts ultimate progression-free survival during treatment. We optimize tissue-free variant calling from plasma samples to facilitate ctDNA monitoring and demonstrate the importance of accounting for persistent clonal hematopoiesis variants. We show that mid-CRT ctDNA concentration is prognostic for disease progression and integrate additional pre-CRT risk factors, including radiomics, into a combined model that improves outcome prediction. Our results suggest that tumor features, radiomics, and mid-CRT ctDNA analysis are complementary and can identify patients at high and low risk of progression to potentially enable response-adapted therapies. Significance: This study demonstrates that combining tumor features, radiomics, and ctDNA analysis improves outcome prediction in NSCLC treated with CRT therapy. Our integrated model could enable personalized and response-adapted therapies to reduce toxicity and improve outcomes in patients. See related commentary by Anagnostou and Aggarwal, p. 1534
Increased Risk of Myocardial Infarction in Inclusion Body Myositis: A Non‐Concurrent Cohort Study
Beecher, Grayson , Muhammad, Sara, Shammas, Ibrahim , Mandrekar, Jay , Harmsen, William S. , Naddaf, Elie , Larson, Kathryn, Naddaf, Elie , Beecher, Grayson , Chamberlain, Alanna M. , Larson, Kathryn F.

European Journal of Neurology | April 29, 2025 | Volume: 32 | Issue: 5 | Pages: No page available

10.1111/ene.70177 | PMID 40297918 Get It

ABSTRACTBackgroundIdiopathic inflammatory myopathies, beyond inclusion body myositis (IBM), have demonstrated an increased risk of adverse cardiovascular outcomes, particularly myocardial infarction (MI). This study evaluated the risk of cardiovascular disease in IBM.MethodsWe conducted a non‐concurrent cohort study utilizing the expanded Rochester Epidemiologic Project, including 50 patients with IBM, matched 1:6 to age‐, sex‐, and calendar year‐matched referents without IBM. Baseline cardiovascular risk factors were recorded. Differences in baseline covariates were adjusted by the inverse probability of treatment weighting method. Participants were followed from the index date forward to determine relative risks (RR) and hazard ratios (HR) for the development of cardiovascular outcomes including MI, ischemic stroke, cardiomyopathy, congestive heart failure (CHF), and peripheral vascular disease (PVD).Results50 patients with IBM and 294 matched population referents were included. Baseline cardiovascular risk factors were similar between groups. Aspirin use was more common (28% vs. 18%, p = 0.03) and statin use less common (26% vs. 38%, p = 0.04) in IBM versus referents. Patients with IBM had an increased hazard of MI compared to referents [HR: 5.79, 95% CI (2.51, 13.36)]. The risk of MI remained consistently elevated across all models, after accounting for potential confounders. For PVD, 16/50 IBM patients versus 16/287 referents were excluded due to pre‐existing PVD at index (p < 0.001). Among remaining participants, RR for PVD was 2.38 (0.82, 6.9). IBM was not associated with an increased risk of ischemic stroke, cardiomyopathy, or CHF.ConclusionsIBM is associated with increased risk of MI compared to population referents. Heightened cardiovascular monitoring and prevention strategies are needed in IBM.
Resection of a Cerebellopontine Angle Ependymoma Using a Far Lateral Approach: 2-Dimensional Operative Video
Naylor, Ryan M. , Mensah‐Brown, Kobina , Graepel, Stephen , Celda, María Peris, Mensah-Brown, Kobie, De Bonis, Alessandro, Graepel, Stephen P, Peris Celda, Maria, Bonis, Alessandro De

Operative Neurosurgery | April 29, 2025 | Volume: 30 | Issue: 2 | Pages: 330-330

10.1227/ons.0000000000001593 | PMID 40298388 Get It

Efficacy and Safety of Recombinant Human Prourokinase in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Sabet, Haneen , Abbas, Abdallah , El-Moslemani, Mohamed , Zanaty, Mohamed Ahmed , Kadirvel, Ramanathan , Ghozy, Sherief

Brain Sciences | April 29, 2025 | Volume: 15 | Issue: 5 | Pages: 466

10.3390/brainsci15050466 | PMID 40426637 Get It

Objective: To evaluate the safety and efficacy of recombinant human prourokinase (rhPro-UK) administered via intravenous (IV) and intra-arterial (IA) routes in acute ischemic stroke (AIS) patients compared with standard treatments. Methods: A comprehensive search was conducted in accordance with PRISMA guidelines across Scopus, Web of Science, and PubMed until 11 December 2024. Randomized controlled trials (RCTs) assessing rhPro-UK’s efficacy and safety were included. Outcomes included the modified Rankin Scale (mRS), the National Institutes of Health Stroke Scale (NIHSS), mortality, and adverse events (AEs). Data analysis used risk difference (RD) with 95% confidence intervals (CIs). Results: Six RCTs (n = 3993) met the inclusion criteria. IV rhPro-UK showed comparable efficacy to the comparator for the mRS 0–1 at 90 days (RD: 0.00, 95% CI: [−0.04, 0.04]) and the mRS 0–2 (RD: −0.01, 95% CI: [−0.03, 0.01], P = 0.23). IA rhPro-UK significantly improved the mRS 0–1 (RD: 0.13, 95% CI: [0.01, 0.26], P = 0.04). The NIHSS reduction was significant for IV rhPro-UK (MD: −0.83, 95% [CI: −1.36, −0.29]). IV rhPro-UK did not significantly reduce the risk of systemic bleeding (RD: −0.10, 95% CI: [−0.24, 0.03], P = 0.12), serious AEs (RD: −0.01, 95% CI: [−0.04, 0.02], P = 0.53), or mortality (RD: 0.01, 95% CI: −0.01, 0.02). IA rhPro-UK significantly increased hemorrhage with neurological deterioration (RD: 0.08, 95% CI: [0.01, 0.14], P = 0.02). Conclusions: IV rhPro-UK provides non-inferior efficacy to both alteplase and standard care with a better safety profile at 35 mg, while IA rhPro-UK enhances functional outcomes in middle cerebral artery occlusions, albeit with safety concerns. Further trials are needed to confirm long-term outcomes, optimal dosing, and broader applicability.